Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer
- 11 August 2022
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 387 (6) , 573-574
Abstract
To the Editor: According to Leidner et al. (June 2 issue),1 anti–KRAS G12D T-cell treatment produced a partial response in a patient with pancreatic ductal adenocarcinoma and metachronous lung metastases. We bring up two points that may aid in understanding the underlying reasons and guide patient selection. First, patients with pancreatic ductal adenocarcinoma who have the lung as the sole site of metastasis form a distinct subgroup of patients with favorable clinical outcomes, which is hypothesized to be aided by immunity.2 Second, the T cells used had a tissue-resident phenotype with high CD103 expression, which is known to correlate tightly . . .Keywords
This publication has 10 references indexed in Scilit:
- Neoantigen T-Cell Receptor Gene Therapy in Pancreatic CancerNew England Journal of Medicine, 2022
- Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 studyESMO Open, 2022
- Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous LymphocytesJournal of Clinical Oncology, 2022
- CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancerJournal for ImmunoTherapy of Cancer, 2021
- Pancreatic CancerJAMA, 2021
- CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironmentCell, 2021
- T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumoursNature Biomedical Engineering, 2021
- A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus–associated Epithelial CancersClinical Cancer Research, 2019
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial CancerScience, 2014
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer ImmunotherapyClinical Cancer Research, 2011